Market LIVE
Published markets; coverage varies by country
Product profile · United States

Osenvelt

 ·  Patent Litigation & Settlement History ↓

Ingredientdenosumab-bmwo
Application typeBLA
Application761404
Product002
Dosage formInjection
RouteSubcutaneous
Strength120MG/1.7ML (70MG/ML)
Approval date2025-02-28
Marketing statusPrescription
Status event—
ApplicantCELLTRION INC
Product source

Current GenericRadar decision

Year2025
SelectionDEEP_REVIEW
ReviewFINAL
Anchor typeTRUE_DS
Anchor date2025-02-19
Patent anchor2025-02-19
Exclusivity anchor2022-06-01
Protection date—
First Final ANDA—
Status event—

GNR judgment: DEEP_REVIEW. Reference year: 2025. Anchor type: TRUE_DS. Patent anchor: 2025-02-19. Exclusivity anchor: 2022-06-01. Anchor date: 2025-02-19. Patent tail: not established. Exclusivity tail: not established. Review status: FINAL. Historical detailed rationale is retained in the evidence snapshot; this is a structured English summary, not a literal translation.

Patent estate

PatentEffective dateOfficial listingTRUE_DSDS gradeClaim classification / basisPTEPEDFamily
No patent facts are recorded for this product.

Regulatory exclusivity

CodeStart dateEnd dateScopeEntire productAll indicationsFull coverage dateCombinationSource
No exclusivity facts are recorded in this product snapshot.

2026-10-10 · PENDING_EXCLUSIVITY_CONFIRMATION · Historical coverage: NOT_COMPLETE

Generic approval evidence

Application / productEventFinal dateTentative dateApplicantAuthorized genericExact mappingSource
No generic approval facts are linked to this product.

Market Entry Information

API filings, authorized generics and linked regulatory milestones.

API Master Files & Certifications 0 records

Ingredient-level registrations from linked public manufacturer portfolios. A filing does not establish supply to this finished product. DMFs are not FDA approvals.

APIHolder / manufacturerHolder countryFiling typeNumberStatusFiled dateAvailable for referenceSourceLast verified
No master-file or certification records are linked through public manufacturer portfolios.

Authorized Generics 0 records

Authorized generics are shown separately from independent ANDA approvals.

Application / productApplicantEvent / status First marketed Product mappingSourceLast verified
No authorized-generic records are linked to this product.

Tentative ANDA Approvals 0 records

Tentative approval is not final approval. Historical tentative approvals remain visible after a linked final approval.

Application / productApplicantEvent / status Tentative date Follow-up final approvalProduct mappingSourceLast verified
No tentative-approval records are linked to this product.

Paragraph IV Challenges 0 records

Paragraph IV challenges below are sourced from legal records separately from FDA approvals. An ANDA filing, lawsuit or settlement does not establish final approval or commercial launch.

Application / productApplicantEvent / status Certification event date Product mappingSourceLast verified
No structured Paragraph IV certification events are linked in the available approval evidence.

Final ANDA Approvals 0 records

Approval dates do not establish commercial launch. Product mapping is shown for each linked record.

Application / productApplicantEvent / status Final approval date Product mappingSourceLast verified
No final-approval records are linked to this product.
Decision evidence (1)
TypeDateRoleBasisSource
BLA_PATENT_EXCLUSIVITY_REVIEW—BUSINESS_CLASSIFICATION_WITH_CONDITIONSEnglish description not available.Source
Decision history
CurrentYearStatusReviewAnchorJudged
Y2025DEEP_REVIEWFINAL2025-02-192026-10-19 10:14:06
N2025DEEP_REVIEWFINAL_CHECKING2025-02-192026-10-19 04:02:04
Independent legal-event information

Litigation & Settlement History

Settlement launch rights generally apply only to the named parties and product scope. These records do not change GenericRadar patent/exclusivity anchors or current decisions.

No litigation or settlement record currently linked to this product.